Angiodynamics Offers New, High Flexibility Rfa Device For Cancer Tumor Ablation | AngioDynamics, Inc.
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Healthcare Company News AngioDynamics, Inc. Angiodynamics Offers New, High Flexibility Rfa Device For Cancer Tumor Ablation

Angiodynamics Offers New, High Flexibility Rfa Device For Cancer Tumor Ablation

Company News - AngioDynamics, Inc.

Angiodynamics new StarBurst XLi-Enhanced Semi-Flex probe is the first RFA device for cancer tumor ablation

The new StarBurst XLi-Enhanced Semi-Flex probe from AngioDynamics (NASDAQ: ANGO) is the first radiofrequency ablation (RFA) device specifically designed to deliver a 7cm ablation of a tumor in a single placement during Computed Tomography-aided procedures.

“The Semi Flex XLi-Enhanced probe will allow us to reach and treat tumors that were previously untreatable by percutaneous radiofrequency ablation,” said Dr. Kevin Hirsch, Interventional Radiologist and Chairman of the Department of Radiology at Banner Good Samaritan Medical Center. “We are very excited for our patients.”

The StarBurst series of devices deploy radiofrequency electrode tines – from the end a long wand inserted into the body percutaneously – to raise the temperature of cells above 45-50°C and cause cellular death. Used by surgical oncologists, hepatobiliary surgeons, liver transplant surgeons, laparoscopists and interventional radiologists, these systems offer patients with unresectable liver lesions an effective treatment option with few side effects or complications.

Physicians can now call upon a single device with both the ablation capability of the StarBurst XLi-Enhanced probe, and the flexibility of the Semi-Flex device and its ability to maneuver around a Computed Tomography (CT) gantry. The StarBurst XLi-Enhanced Semi-Flex reduces the time required to perform procedures and can enable patients to resume normal activity within days.

“AngioDynamics’ radiofrequency devices have the lowest local tumor recurrence following treatment of all three RFA devices on the US market,” said Jan Keltjens, AngioDynamics CEO. “This new tool continues to build on our market leadership.”

The scalable design can create ablations from 4-7cm, allowing physicians procedural flexibility. The device also gives dynamic, real-time temperature readouts and needle track ablation. The design provides superior ergonomics and clinician controls. An infusion-based system increases conductivity of the ablation zone, and an integrated tubing set allows for easy set up.

The new device is versatile with both rigid metal and flexible polymer trocar sections. Its ability to bend up to 90 degrees in all directions enables easy gantry entrance for CT systems. It can be used for percutaneous, laparoscopic and intraoperative procedures.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment peripheral vascular disease and cancer. The Company’s diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.

Source: Angiodynamics